Abstract

Significant liver inflammation might be found in 20–34% of chronic hepatitis B virus (HBV) infection patients with detectable HBV DNA and persistently normal alanine transaminase (ALT) (PNALT). We aimed to develop a diagnostic algorithm to predict significant liver inflammation in these specific patients. Using liver biopsy as the gold standard, we developed a novel, simple diagnostic algorithm to predict significant liver inflammation in a training set of 365 chronic HBV infection patients with detectable HBV DNA and PNALT, and validated the diagnostic accuracy in a validation set of 164 similar patients. The novel algorithm (AAGP) attributed to age, ALT, gamma-glutamyl transpeptidase (GGT), and platelet count was developed. In the training set, the area under the receiver operating characteristic curve (AUROC) of AAGP was higher than that of ALT and aspartate transaminase (AST), to diagnose significant liver inflammation (0.77, 0.67, and 0.59, respectively, p < 0.001). In the validation set, the AUROC of AAGP was also higher than ALT and AST (0.75, 0.61, and 0.54, respectively, p < 0.001). Using AAGP ≥2, the sensitivity and negative predictive value (NPV) was 91% and 93%, respectively, to diagnose significant liver inflammation. Using AAGP ≥8, the specificity and NPV was 91% and 86%, respectively, for significant liver inflammation. In conclusion, the AAGP algorithm is a novel, simple, user-friendly algorithm for the diagnosis of significant liver inflammation in chronic HBV infection patients with detectable HBV DNA and PNALT.

Highlights

  • Infection with hepatitis B virus (HBV) is a public health problem worldwide, and 240 million people estimated to experience chronic HBV infection1

  • Previous studies revealed that significant liver inflammation might be found in 20–34% of chronic HBV infection patients with detectable HBV DNA and persistently normal alanine transaminase (ALT) (PNALT)8–10

  • Significant liver inflammation might be found in 20–34% of chronic HBV infection patients with detectable HBV DNA and PNALT8–10, and 5.7% of chronic HBV infection patients with undetectable HBV DNA and PNALT11

Read more

Summary

Introduction

Infection with hepatitis B virus (HBV) is a public health problem worldwide, and 240 million people estimated to experience chronic HBV infection. Among chronic HBV infection patients, those with significant liver inflammation have a much greater risk of cirrhosis, liver de-compensation, and HCC3. Biochemical test is usually used to diagnose liver inflammation because of its inexpensive and non-invasive advantages. Previous studies revealed that significant liver inflammation might be found in 20–34% of chronic HBV infection patients with detectable HBV DNA and persistently normal ALT (PNALT). Another study found 5.7% of chronic HBV infection patients with undetectable HBV DNA and PNALT had significant liver inflammation. New noninvasive methods for the diagnosis of significant liver inflammation are needed urgently, especially in chronic HBV infection patients with detectable HBV DNA and PNALT.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call